Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMC

ERp46 mitigates lipotoxic ER stress to preserve GLUT2 expression and insulin secretion in β-cells

Chen D., Chen X., Tian Y., Wang K., Han C.

Laboratory Study on Type 2 Diabetes, published in Biomed Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Biomed Rep (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41384131
PMCID
PMC12690449
DOI
10.3892/br.2025.2095

Abstract (original English)

Lipotoxicity-induced β-cell dysfunction is a critical contributor to the pathogenesis of type 2 diabetes mellitus. The aim of the present study was to investigate the role of endoplasmic reticulum-resident protein 46 (ERp46) in regulating glucose transporter 2 (GLUT2) expression and insulin secretion in β-cells under palmitic acid (PA)-induced lipotoxic stress. β-TC6 cells were treated with PA to induce lipotoxicity, and ERp46 expression was silenced using specific small interfering RNA. GLUT2 expression and insulin secretion were assessed, and the involvement of protein kinase B (AKT) signaling was evaluated. The results demonstrated that PA significantly decreased GLUT2 expression and insulin secretion, while ERp46 expression was upregulated as a potential compensatory response. ERp46 knockdown exacerbated the reduction of GLUT2 expression and insulin secretion. Furthermore, PA treatment reduced phosphorylated AKT (p-AKT) levels without altering total AKT expression, and ERp46 knockdown further decreased p-AKT levels. The activation of AKT using AKT activator compound SC79 restored GLUT2 expression and insulin secretion in ERp46-depleted cells. These findings indicated that ERp46 helps preserve β-cell function under lipotoxic stress, potentially by stabilizing ER proteostasis and supporting AKT phosphorylation.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research